問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



Chang Gung Medical Foundation Chang Gung Memorial Hospital, Keelung

Link to Hospital

  • 1,089

    Total Beds

  • 275

    Total Doctors

  • shengyuan@cgmh.org.tw
  • Lin, Sheng-yuan
  • 02-24329292 #2082
  • 204Keelung CityAn LeNo. 222, Maijin Rd., Anle Dist., Keelung City 204015, Taiwan

Recruiting Trial

63Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

176Cases

2011-09-30 - 2013-09-30

Others

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2009-12-01 - 2013-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Terminated12Sites

2012-09-01 - 2015-12-31

Phase II/III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Study ended6Sites

2020-08-01 - 2022-07-31

Others

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2018-08-01 - 2023-07-31

Others

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2014-04-01 - 2017-09-30

Others

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2015-01-01 - 2016-07-31

Others

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2019-06-15 - 2023-09-14

Phase II

A Phase 2, Randomized, Double-blind, Placebo-controlled Study of Cemdisiran in Adult Patients With IgA Nephropathy

  • Condition/Disease

    IgA Nephropathy

  • Test Drug

    Cemdisiran (ALN-CC5)

Participate Sites
6Sites

Recruiting6Sites

2017-08-10 - 2021-06-30

Phase III

A Randomized Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab Combined with Fluorouracil plus Cisplatin versus Fluorouracil plus Cisplatin in Subjects with Unresectable Advanced, Recurrent or Metastatic Previously Untreated Esophageal Squamous Cell Carcinoma

  • Condition/Disease

    Esophageal Squamous Cell Carcinoma

  • Test Drug

    Nivolumab/Ipilimumab

Participate Sites
15Sites

Terminated13Sites

林振源
China Medical University Hospital-Taipei

未分科

陳明晃
Taipei Veterans General Hospital

Division of Hematology & Oncology

2016-12-01 - 2021-11-30

Phase III

A phase 3 randomized, open-label (sponsor-blind), active-controlled, parallel-group, multi-center, event driven study in non-dialysis subjects with anemia associated with chronic kidney disease to evaluate the safety and efficacy of daprodustat compared to darbepoetin alfa

  • Condition/Disease

    non-dialysis with anemia associated with chronic kidney disease

  • Test Drug

    Daprodustat (GSK1278863)

Participate Sites
12Sites

Recruiting7Sites

Terminated5Sites

蘇裕謀
Taipei WanFang Hospital (Managed by Taipei Medical Univeristy)

Division of Nephrology

1 9 10 11 12 13 18
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB